This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Hann, H.-W. L. Articles by Blumberg, B. S. Search for Related Content PubMed PubMed Citation Articles by Hann, H.-W. L. Articles by Blumberg, B. S.

Iron Nutrition and Tumor Growth: Decreased Tumor Growth in Iron-deficient Mice¹

Fax Chase Cancer Center, Philadelphia, Pennsylvania 19111

Groups of 15 mice of three different laboratory strains (BALB/c, C3H/He, DBA/2) were fed on a low iron diet (5 mg iron/kg diet), and three similar groups of 15 mice were maintained on a normal iron diet (312 mg iron/kg diet). When the low iron diet group became iron deficient, tumor cells (5 x 10⁵ cells/mouse) of CA07-A (colon adenocarcinoma), HE129 (hepatoma), and M119 (mammary adenocarcinoma) were inoculated s.c. in BALB/c, C3H/He, and DBA/2 mice, respectively. All mice developed tumors, tumors grew more slowly, and the mean tumor sizes were smaller in the low iron diet group at nearly all weekly observations in all three strains of mice. No apparent differences in the behavior, activity (e.g., movement, climbing, running, grooming, etc.), and appearance were observed between low iron diet and normal iron diet mice. The mean body weight of mice at transplantation was less in the low iron than in the normal iron groups for the BALB/c strain but higher in the low iron groups of C3H/He and DBA/2 mice, indicating that food intake of mice on a low iron diet was not impaired. These results suggest that iron nutrition of the host affects tumor growth; tumor cells grow better in an iron-rich environment. This knowledge should be considered when designing treatment for patients with cancer. Iron oversupply in cancer patients might enhance tumor growth and adversely affect cancer therapy.

¹ This work was supported by USPHS Grants CA-40737, RR-05895, CA-06927, and CA-39949 from the NIH and by an appropriation from the Commonwealth of Pennsylvania.

² To whom requests for reprints should be addressed.

Received 9/22/87. Revised 12/21/87. Accepted 4/ 4/88.

This article has been cited by other articles:

				L. R. Zacharski, B. K. Chow, P. S. Howes, G. Shamayeva, J. A. Baron, R. L. Dalman, D. J. Malenka, C. K. Ozaki, and P. W. Lavori Decreased Cancer Risk After Iron Reduction in Patients With Peripheral Arterial Disease: Results From a Randomized Trial J Natl Cancer Inst, July 16, 2008; 100(14): 996 - 1002. [Abstract] [Full Text] [PDF]

				N. J. Shaheen, L. M. Silverman, T. Keku, L. B. Lawrence, E. M. Rohlfs, C. F. Martin, J. Galanko, and R. S. Sandler Association Between Hemochromatosis (HFE) Gene Mutation Carrier Status and the Risk of Colon Cancer J Natl Cancer Inst, January 15, 2003; 95(2): 154 - 159. [Abstract] [Full Text] [PDF]

				N. Rakba, P. Loyer, D. Gilot, J. G. Delcros, D. Glaise, P. Baret, J. L. Pierre, P. Brissot, and G. Lescoat Antiproliferative and apoptotic effects of O-Trensox, a new synthetic iron chelator, on differentiated human hepatoma cell lines Carcinogenesis, May 1, 2000; 21(5): 943 - 951. [Abstract] [Full Text] [PDF]

				L.E. Beckman, G.F. Van Landeghem, C. Sikstrom, A. Wahlin, B. Markevarn, G. Hallmans, P. Lenner, L. Athlin, R. Stenling, and L. Beckman Interaction between haemochromatosis and transferrin receptor genes in different neoplastic disorders Carcinogenesis, July 1, 1999; 20(7): 1231 - 1233. [Abstract] [Full Text] [PDF]